News

Phlow Corp. Receives HHS Small Business Prime Contractor of the Year Award

The U.S. Department of Health and Human Services (HHS), recently awarded Phlow Corp. the Office of Small and Disadvantaged Business Utilization (OSDBU), Small Business Prime Contractor of the Year Award. Phlow Corp. is a U.S.-based, public benefit corporation committed to solving America’s broken essential medicine supply chain. This award recognizes Phlow for its performance during the previous fiscal year on its contract with HHS.

“We are honored to receive this recognition from HHS as we work together to reliably supply affordable, high-quality, essential medicines through U.S.-based advanced manufacturing processes,” said Eric Edwards, M.D., Ph.D., co-founder, President, and CEO of Phlow. “We are thrilled to continue expanding our existing relationship with the U.S. Government to create a resilient and sustainable essential medicines supply chain that will benefit all Americans.”

Phlow’s vision is to make the U.S. a country where every human being has access to the essential medicines necessary to sustain life and conquer disease. Throughout 2020 and 2021, Phlow has worked toward strengthening the U.S. essential medicines supply chain by offering a novel, resilient, end-to-end solution that is U.S.-based, comprehensive, and fully integrated.

The U.S. Government and Phlow recognize the importance of enhancing domestic manufacturing as well as providing diversity in the essential medicine supply chain by leveraging private sector partnerships to achieve essential medicine supply chain resilience. With contract funding support from the Biomedical Advanced Research and Development Authority (BARDA), part of the office of Assistant Secretary for Preparedness and Response (ASPR) at HHS, Phlow is currently developing a comprehensive advanced development and manufacturing infrastructure, including a Strategic Active Pharmaceutical Ingredient Reserve (“SAPIR”), intended to help ensure the U.S. has an uninterrupted supply of affordable essential life-saving medicine ingredients that can be rapidly converted to finished essential medicines to meet increasing demands due to supply chain disruptions whether from trade challenges, international conflicts, natural disasters, or future public health emergencies.

Recent News

09/22/2021

Activation Capital $15,000 Pitch Contest in November to Shine Light on Virginia Businesses

The inaugural Pitch Virginia event, powered by Activation Capital, will take place on Wednesday, November 10 at the newly opened Shift Retail Lab at VCU, an initiative of the VCU da Vinci Center.  Kicking off with a design thinking workshop in the morning, the day will be filled with pitches from high growth, main street

09/22/2021

Caretaker Medical Chosen as Finalist to Compete for $350,000 Grand Prize at MedTech Conference

This year brought in a record number of applications with over 1,100 submissions from 54 countries and 42 U.S. states. With less than a 5% acceptance rate, 50 companies were selected to participate in the MedTech Innovator Showcase, with a subset receiving a place in the MedTech Innovator Accelerator. Over four months, 25 Accelerator companies

09/21/2021

HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics Gout Discovery Pipeline

HemoShear Therapeutics, a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). This milestone marks the fourth payment that HemoShear has earned, following previous payments for the identification and validation of